Losartan Potassium has 20 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 9 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Aliskiren, Agents Increasing Serum Potassium, Amiloride. Patients taking Losartan Potassium should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 20
- Contraindicated
- 1
- Major
- 9
- Moderate
- 6
- Minor
- 4
Contraindicated (1)
- Losartan Potassium + Aliskiren— Contraindicated in patients with diabetes. Avoid use in patients with renal impairment (GFR <60 mL/min). Associated with…
Major (9)
- Losartan Potassium + Agents Increasing Serum Potassium— Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.
- Losartan Potassium + Amiloride— Concomitant use may lead to increases in serum potassium, which can be serious.
- Losartan Potassium + Lisinopril— Dual RAS blockade increases risks of hypotension, syncope, hyperkalemia, and acute kidney injury compared to monotherapy…
- Losartan Potassium + Lithium— Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration. Mon…
- Losartan Potassium + Mao Inhibitors— Dual blockade of RAS associated with increased risks of hypotension, syncope, hyperkalemia, and acute renal failure. Avo…
- Losartan Potassium + Nsaids— May result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-dep…
- Losartan Potassium + Potassium Supplements— Concomitant use of losartan and potassium supplements may lead to increases in serum potassium.
- Losartan Potassium + Spironolactone— Concomitant use may lead to increases in serum potassium, which can be serious.
- Losartan Potassium + Triamterene— Concomitant use may lead to increases in serum potassium, which can be serious.
Moderate (6)
- Losartan Potassium + Cimetidine— Coadministration led to an increase of about 18% in AUC of losartan but did not affect the pharmacokinetics of its activ…
- Losartan Potassium + Erythromycin— AUC of active metabolite was not affected but AUC of losartan was increased by 30%.
- Losartan Potassium + Fluconazole— Decreased AUC of active metabolite by approximately 40% but increased AUC of losartan by approximately 70%.
- Losartan Potassium + Losartan— ( 7.4 ) 7.1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium l…
- Losartan Potassium + Phenobarbital— Coadministration led to a reduction of about 20% in the AUC of losartan and its active metabolite.
- Losartan Potassium + Rifampin— Approximately 40% reduction in AUC of active metabolite and 30% reduction in AUC of losartan.
Minor (4)
- Losartan Potassium + Digoxin— Losartan did not affect the pharmacokinetics of oral or intravenous digoxin.
- Losartan Potassium + Hydrochlorothiazide— No pharmacokinetic interaction between losartan and hydrochlorothiazide.
- Losartan Potassium + Ketoconazole— Conversion of losartan to its active metabolite after intravenous administration is not affected by ketoconazole.
- Losartan Potassium + Warfarin— Losartan did not affect the pharmacokinetics or pharmacodynamics of warfarin.